Metacrine, Inc.
CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST

Last updated:

Abstract:

Described herein is the farnesoid X receptor agonist, trans-N-(3-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl)-4-hydroxy-N-((trans-4-(- 4-methoxy-3-methyl phenyl)cyclohexyl)methyl)cyclohexane-carboxamide, including crystalline forms and pharmaceutically acceptable salts, solvates, and formulations thereof.

Status:
Application
Type:

Utility

Filling date:

17 Sep 2019

Issue date:

11 Nov 2021